# Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

> **NCT03424473** · — · NO_LONGER_AVAILABLE · sponsor: **Seagen Inc.**

## Conditions studied

_None listed._

## Interventions

- **DRUG:** Tucatinib

## Key facts

- **NCT ID:** NCT03424473
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03424473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03424473, "Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03424473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*